

Title (en)  
BIOENHANCED COMPOSITIONS

Title (de)  
BIOLOGISCH VERBESSERTE ZUSAMMENSETZUNGEN

Title (fr)  
COMPOSITIONS AMELIOREES BIOLOGIQUEMENT

Publication  
**EP 1877042 A4 20110302 (EN)**

Application  
**EP 06750455 A 20060418**

Priority  
• US 2006014422 W 20060418  
• IN 315MU2006 A 20060306  
• IN 477MU2005 A 20050418

Abstract (en)  
[origin: WO2006113631A2] The present invention relates to the method of increasing the bioavailability of Angiotensin II Receptor Blockers (ARBs) by preparing a composition of an ARB with at least one solubility enhancing agent. In particular, the present invention relates to solubility enhancing agents that not only act as solubility enhancers but also improve the dissolution rate particularly in acidic or mildly acidic media, where solubility of the ARB is minimal. In the composition, the ARB may be present in the form of physical blend, solid dispersion, solid solution or complex with the solubility enhancing agent. The composition of an ARB with solubility enhancing agent can be incorporated in an immediate release or a controlled release or any other suitable modified release formulation. Immediate release dosage forms containing the composition of an ARB give an in vitro release of at least 40% in acidic media (pH < 3). As a result, the bioavailability of the ARB can be increased by at least 20% as measured by C<sub>max</sub>, AUC<sub>0-t</sub> and AUC<sub>0-8</sub>.

IPC 8 full level  
**A61K 9/20** (2006.01); **A61K 9/50** (2006.01)

CPC (source: EP KR)  
**A61K 9/145** (2013.01 - EP); **A61K 9/146** (2013.01 - EP); **A61K 9/1617** (2013.01 - EP); **A61K 9/20** (2013.01 - KR); **A61K 9/2013** (2013.01 - EP); **A61K 9/2054** (2013.01 - EP); **A61K 9/2077** (2013.01 - EP); **A61K 9/48** (2013.01 - KR); **A61K 9/4858** (2013.01 - EP); **A61K 9/4866** (2013.01 - EP); **A61K 31/352** (2013.01 - KR); **A61K 47/30** (2013.01 - KR); **A61P 9/00** (2017.12 - EP); **A61P 9/04** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/12** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 25/22** (2017.12 - EP); **A61P 25/24** (2017.12 - EP); **A61P 25/28** (2017.12 - EP)

Citation (search report)  
• [XP] WO 2005041929 A1 20050512 - LIPOCINE INC [US], et al  
• [Y] US 2003152622 A1 20030814 - LOUIE-HELM JENNY [US], et al  
• [Y] US 2003180352 A1 20030925 - PATEL MAHESH V [US], et al  
• [XY] WO 2004105694 A2 20041209 - LIPOCINE INC [US], et al  
• [XP] WO 2005056607 A1 20050623 - BELUPO LIJEKOVI I KOZMETIKA D [HR], et al  
• [Y] FOGARI, R. ET AL: "Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring", CURRENT THERAPEUTIC RESEARCH, vol. 60, no. 4, April 1999 (1999-04-01), pages 195 - 206, XP002575013  
• See references of WO 2006113631A2

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**WO 2006113631 A2 20061026; WO 2006113631 A3 20061214**; AU 2006236497 A1 20061026; CA 2605183 A1 20061026; EP 1877042 A2 20080116; EP 1877042 A4 20110302; IL 186721 A0 20080209; JP 2008536929 A 20080911; KR 20080042039 A 20080514; MX 2007012947 A 20080409

DOCDB simple family (application)  
**US 2006014422 W 20060418**; AU 2006236497 A 20060418; CA 2605183 A 20060418; EP 06750455 A 20060418; IL 18672107 A 20071017; JP 2008507777 A 20060418; KR 20077026647 A 20071115; MX 2007012947 A 20060418